Gene Therapy Also Effective in Younger Children With Inherited Blood Disorders

(MedPage Today) — ORLANDO — The gene therapy exagamglogene autotemcel (exa-cel; Casgevy) — already approved for patients 12 years and older with transfusion-dependent beta-thalassemia (TDT) and sickle cell disease (SCD) — led to durable…